DCAF6抗体;DCAF6 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P12001(DCAF6 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P12001(DCAF6 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The DCAF6 (DDB1- and CUL4-associated factor 6) antibody is a research tool targeting the DCAF6 protein, a substrate receptor component of the CUL4-DDB1 E3 ubiquitin ligase complex. DCAF6 plays a critical role in the ubiquitin-proteasome system by recruiting specific substrates for ubiquitination and subsequent degradation. It is involved in diverse cellular processes, including cell cycle regulation, DNA damage response, and protein homeostasis. Dysregulation of DCAF6 has been implicated in cancer, neurological disorders, and viral pathogenesis, making it a subject of interest in disease mechanism studies.

Antibodies against DCAF6 are used to investigate its expression, localization, and interactions in various biological contexts. They enable techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to explore DCAF6's functional roles and regulatory networks. Recent studies highlight its involvement in modulating Wnt/β-catenin signaling and its interaction with viral proteins, suggesting therapeutic targeting potential. Commercial DCAF6 antibodies are typically validated for specificity across human, mouse, and rat models, though variability in isoform detection requires careful experimental design. Ongoing research aims to clarify its tissue-specific functions and therapeutic relevance in diseases linked to ubiquitination pathways.